Compare Biocon with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs PFIZER - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON PFIZER BIOCON /
PFIZER
 
P/E (TTM) x 32.5 42.7 76.1% View Chart
P/BV x 3.9 7.1 54.6% View Chart
Dividend Yield % 0.3 0.5 52.7%  

Financials

 BIOCON    PFIZER
EQUITY SHARE DATA
    BIOCON
Mar-19
PFIZER
Mar-19
BIOCON /
PFIZER
5-Yr Chart
Click to enlarge
High Rs7073,840 18.4%   
Low Rs5542,080 26.6%   
Sales per share (Unadj.) Rs91.9455.0 20.2%  
Earnings per share (Unadj.) Rs16.793.8 17.8%  
Cash flow per share (Unadj.) Rs24.2109.4 22.1%  
Dividends per share (Unadj.) Rs1.0022.50 4.4%  
Dividend yield (eoy) %0.20.8 20.9%  
Book value per share (Unadj.) Rs101.6658.2 15.4%  
Shares outstanding (eoy) m600.0045.75 1,311.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.96.5 105.5%   
Avg P/E ratio x37.731.6 119.6%  
P/CF ratio (eoy) x26.127.1 96.4%  
Price / Book Value ratio x6.24.5 138.0%  
Dividend payout %6.024.0 24.9%   
Avg Mkt Cap Rs m378,330135,420 279.4%   
No. of employees `0006.12.6 233.0%   
Total wages/salary Rs m11,6533,238 359.8%   
Avg. sales/employee Rs Th8,994.37,911.4 113.7%   
Avg. wages/employee Rs Th1,900.71,230.9 154.4%   
Avg. net profit/employee Rs Th1,635.31,630.7 100.3%   
INCOME DATA
Net Sales Rs m55,14420,815 264.9%  
Other income Rs m1,4441,674 86.3%   
Total revenues Rs m56,58822,489 251.6%   
Gross profit Rs m15,8835,712 278.1%  
Depreciation Rs m4,478714 627.3%   
Interest Rs m70973 972.6%   
Profit before tax Rs m12,1406,599 184.0%   
Minority Interest Rs m90-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1232,309 92.0%   
Profit after tax Rs m10,0264,291 233.7%  
Gross profit margin %28.827.4 105.0%  
Effective tax rate %17.535.0 50.0%   
Net profit margin %18.220.6 88.2%  
BALANCE SHEET DATA
Current assets Rs m48,22827,167 177.5%   
Current liabilities Rs m30,3768,917 340.7%   
Net working cap to sales %32.487.7 36.9%  
Current ratio x1.63.0 52.1%  
Inventory Days Days6868 100.7%  
Debtors Days Days8630 284.1%  
Net fixed assets Rs m64,1308,862 723.7%   
Share capital Rs m3,000458 655.7%   
"Free" reserves Rs m57,98029,656 195.5%   
Net worth Rs m60,98030,113 202.5%   
Long term debt Rs m15,76625 63,064.0%   
Total assets Rs m121,92439,400 309.5%  
Interest coverage x18.191.5 19.8%   
Debt to equity ratio x0.30 31,142.5%  
Sales to assets ratio x0.50.5 85.6%   
Return on assets %8.811.1 79.5%  
Return on equity %16.414.2 115.4%  
Return on capital %16.822.1 75.7%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,506428 3,620.4%   
Fx outflow Rs m10,399786 1,322.4%   
Net fx Rs m5,107-358 -1,426.1%   
CASH FLOW
From Operations Rs m11,546978 1,180.5%  
From Investments Rs m-7,138351 -2,032.5%  
From Financial Activity Rs m-2,417-1,099 220.0%  
Net Cashflow Rs m2,103231 911.2%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   WYETH  PIRAMAL ENTERPRISES  NATCO PHARMA  NEULAND LABS  IPCA LABS  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat, GAIL and UPL Among Top Nifty Gainers(Closing)

Indian share markets continued their volatile trend during closing hours today and ended their day on a flat note.

Related Views on News

PFIZER Announces Quarterly Results (3QFY21); Net Profit Up 1.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, PFIZER has posted a net profit of Rs 1 bn (up 1.6% YoY). Sales on the other hand came in at Rs 6 bn (up 10.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

BIOCON Announces Quarterly Results (3QFY21); Net Profit Down 19.7% (Quarterly Result Update)

Jan 25, 2021 | Updated on Jan 25, 2021

For the quarter ended December 2020, BIOCON has posted a net profit of Rs 2 bn (down 19.7% YoY). Sales on the other hand came in at Rs 19 bn (up 5.9% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Mar 8, 2021 (Close)

TRACK BIOCON

BIOCON - SUN PHARMA COMPARISON

COMPARE BIOCON WITH

MARKET STATS